Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.77 CNY | -0.50% |
|
+7.86% | +19.65% |
| Oct. 29 | Hangzhou Tigermed Consulting Books 35% Lower Attributable Profit in Q3 | MT |
| Oct. 29 | Frontage Records Lower Net Profit for Nine Months to September | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 52.5B 7.21B 6.85B 6.39B 5.69B 10.14B 610B 11.13B 79.39B 29.43B 250B 27.07B 26.47B 1,077B | P/E ratio 2024 * |
45.7x | P/E ratio 2025 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise value | 46.81B 6.42B 6.11B 5.69B 5.07B 9.04B 544B 9.92B 70.78B 26.24B 223B 24.14B 23.6B 961B | EV / Sales 2024 * |
6.7x | EV / Sales 2025 * | 5.44x |
| Free-Float |
72.37% | Yield 2024 * |
0.55% | Yield 2025 * | 0.73% |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
| 1 day | -0.50% | ||
| 1 week | +7.86% | ||
| Current month | +1.72% | ||
| 1 month | +5.18% | ||
| 3 months | +32.04% | ||
| 6 months | +22.71% | ||
| Current year | +19.65% |
1 week
62.06
66.73
1 month
59.4770.93
Current year
36.1282.79
1 year
36.1282.79
3 years
36.12144.88
5 years
36.12209.41
10 years
9.68209.41
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | - |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 50 | 2022-10-20 |
Hao Wu
PSD | President | 56 | 2019-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
BRD | Director/Board Member | 55 | 2004-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Zhi Min Chen
BRD | Director/Board Member | 64 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.50% | +7.86% | +5.49% | -51.71% | 7.21B | ||
| -0.51% | +0.93% | +58.07% | -26.11% | 42.79B | ||
| -0.60% | -0.32% | -7.53% | -23.35% | 36.41B | ||
| +1.25% | +6.44% | +14.59% | -5.81% | 27.1B | ||
| -0.27% | +0.40% | -20.92% | -21.93% | 17.58B | ||
| -3.80% | +1.26% | -46.66% | -86.12% | 16.39B | ||
| -0.36% | -2.18% | +53.20% | +98.28% | 16.46B | ||
| -1.28% | +0.24% | +16.23% | -34.19% | 11.92B | ||
| -0.90% | +1.21% | +23.19% | +64.58% | 10.52B | ||
| -0.97% | +0.78% | -1.18% | -44.23% | 10.19B | ||
| Average | -0.22% | +0.87% | +9.45% | -13.06% | 19.66B | |
| Weighted average by Cap. | -0.02% | +0.59% | +14.32% | -14.52% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 6.99B 960M 913M 850M 758M 1.35B 81.28B 1.48B 10.57B 3.92B 33.33B 3.61B 3.52B 143B | 8.43B 1.16B 1.1B 1.03B 914M 1.63B 98.07B 1.79B 12.75B 4.73B 40.21B 4.35B 4.25B 173B |
| Net income | 1.29B 177M 169M 157M 140M 249M 15.02B 274M 1.95B 724M 6.16B 666M 651M 26.5B | 1.93B 265M 252M 234M 209M 372M 22.41B 408M 2.91B 1.08B 9.19B 994M 972M 39.55B |
| Net Debt | -5.69B -781M -743M -692M -617M -1.1B -66.14B -1.21B -8.6B -3.19B -27.12B -2.93B -2.87B -117B | -6.6B -906M -862M -803M -715M -1.27B -76.72B -1.4B -9.98B -3.7B -31.46B -3.4B -3.33B -135B |
More financial data
* Estimated data
Employees
0
Calendar
2025-03-30
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-03 | 65.77 ¥ | -0.50% | 8,200,417 |
| 24-12-02 | 66.10 ¥ | +2.23% | 10,267,030 |
| 24-11-29 | 64.66 ¥ | +3.95% | 12,533,610 |
| 24-11-28 | 62.20 ¥ | -1.58% | 6,516,380 |
| 24-11-27 | 63.20 ¥ | +3.64% | 9,058,460 |
End-of-day quote Shenzhen S.E., December 02, 2024
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
65.77CNY
Average target price
61.04CNY
Spread / Average Target
-7.19%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300347 Stock